To the Editor,
Anaphylaxis is ‘a severe, life-threatening, generalised or systemic hypersensitivity reaction’. It is characterised by rapidly developing features involving one or more of the airways (laryngeal oedema and/or bronchospasm) and circulation (hypotension) often with associated skin and mucosal changes (urticaria, angioedema). Hospital admissions for anaphylaxis are increasing. However, fatalities remain very rare at a stable rate of approximately 20 per year in the UK. This primary care guidance builds on the 2016 British Society of Allergy and Clinical Immunology (BSACI) specialist guideline plus other recent statements (World Allergy Organisation, European Academy Allergy and Clinical Immunology and Resuscitation Council UK). This guidance aims to help risk assess community patients who might be at risk of anaphylaxis.
The guidance was created to address key primary care clinical questions which are informed by current practice and known gaps in care from reported fatalities...
Anaphylaxis is ‘a severe, life-threatening, generalised or systemic hypersensitivity reaction’. It is characterised by rapidly developing features involving one or more of the airways (laryngeal oedema and/or bronchospasm) and circulation (hypotension) often with associated skin and mucosal changes (urticaria, angioedema). Hospital admissions for anaphylaxis are increasing. However, fatalities remain very rare at a stable rate of approximately 20 per year in the UK. This primary care guidance builds on the 2016 British Society of Allergy and Clinical Immunology (BSACI) specialist guideline plus other recent statements (World Allergy Organisation, European Academy Allergy and Clinical Immunology and Resuscitation Council UK). This guidance aims to help risk assess community patients who might be at risk of anaphylaxis.
The guidance was created to address key primary care clinical questions which are informed by current practice and known gaps in care from reported fatalities...
No comments:
Post a Comment